Roche’s Divarasib Shows Competitive Data As Monotherapy In KRAS

 
• By Joseph Haas
KRAS G12C protein
Roche is working to compete with Amgen, Mirati in KRAS inhibition • Source: Shutterstock

More from Clinical Trials

More from R&D